摘要 |
Compounds of general formula I R<SUP>1 </SUP>is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, and pyridine N-oxide; R<SUP>2 </SUP>is independently selected from ethyl and isopropyl; R<SUP>3 </SUP>is independently selected from hydrogen and fluoro; R<SUP>4 </SUP>is independently selected from -OH, -NH<SUB>2 </SUB>and -NHSO<SUB>2</SUB>R<SUP>5</SUP>; and R<SUP>5 </SUP>is independently selected from hydrogen, -CF<SUB>3 </SUB>and C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, or salts thereof or separate enantiomers and salts thereof; where each R<SUP>1 </SUP>heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, NO<SUB>2</SUB>, CF<SUB>3</SUB>, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as separate enantiomers of the compounds and salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders. |